Lasika Seneviratne, MD
Hematology & Oncology · Los Angeles, CANPI 1437268174
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (32.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Novartis at 56.0% of the total. Reporting peaked in 2019 at $45,814 and has fallen 82.6% since, to $7,956 in 2025. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,399 payments — averaging $81.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$64K
- Gilead$6K
- AstraZeneca$6K
- Daiichi Sankyo Inc.$5K
- Genentech USA, Inc.$5K
- G1 Therapeutics, Inc.$3K
- plus $24K from 54 others
Across 698 payments — averaging $11,493 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2.8M
- Genentech, Inc.$927K
- G1 Therapeutics, Inc.$861K
- AstraZeneca$761K
- Beigene, Ltd.$493K
- GSK$476K
- plus $1.7M from 23 others
What the payments were for
- Consulting fees$33,07529%
- Speaking & faculty fees$37,08733%
- Travel & lodging$10,7459%
- Food & beverage$29,85026%
- Education$4770%
- Gifts$8581%
- Other$2,0132%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KISQALI$55,483
- PIQRAY$16,553
- Trodelvy$5,297
- Enhertu$4,406
- TECENTRIQ$3,246
- COSELA$2,474
- Copiktra$1,680
- Venclexta$1,200
- Nerlynx$1,000
- Cabometyx$294
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$165
- TUKYSA$146
- Erleada$145
- MI CANCER SEEK$131
- Stivarga$126
- NUEDEXTA$125
- Yescarta$122
- FOUNDATIONONE$121
- FOUNDATIONONE HEME$121
- FOUNDATIONONE CDX$121
How this compares
$114,104 in reported general payments places this provider in the 90th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 45 | $705,420 |
| IbrancePalbociclib | 41 | $601,171 |
| KisqaliRibociclib Succinate | 30 | $516,524 |
| CalquenceAcalabrutinib Maleate | 20 | $290,438 |
| ProcritEpoetin Alfa | 72 | $200,434 |
| ErleadaApalutamide | 11 | $164,154 |
| Lupron DepotLeuprolide Acetate | 30 | $83,595 |
| ZarxioFilgrastim-Sndz | 29 | $37,077 |
| OrgovyxRelugolix | 13 | $35,236 |
| Abiraterone Acetate | 25 | $26,798 |
| ProliaDenosumab | 14 | $23,368 |
| EliquisApixaban | 15 | $11,201 |
| Deferasirox | 22 | $7,152 |
| Anastrozole | 248 | $5,099 |
| Zoledronic Acid | 15 | $3,211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $1,189 | $705,42045 claims |
| PfizerIbrance, Eliquis | $1,369 | $612,37256 claims |
| NovartisKisqali | $63,880 | $516,52430 claims |
| Johnson & JohnsonProcrit, Erleada | $1,144 | $364,58883 claims |
| AstraZenecaCalquence | $6,095 | $290,43820 claims |
| AbbVieLupron Depot | $1,596 | $83,59530 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $80 | $35,23613 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $145 | $26,79825 claims |
| AmgenProlia | $1,714 | $23,36814 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $79 | $8312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Los Angeles
- Dennis SlamonLos Angeles$3.1M
- George YaghmourLos Angeles$1.9M
- Kevin KellyLos Angeles$894K
- Raghuveer RanganathanLos Angeles$609K
- Matthew RettigLos Angeles$442K
- David BerzLos Angeles$420K
- Gottfried KonecnyLos Angeles$402K
- Antoni RibasLos Angeles$315K
- Edward GaronLos Angeles$301K
- Rahul NaikLos Angeles$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.